the thank and Thank morning, you you, everyone, Good joining call. for Dave.
of transformational next-generation on achievements we expanded financially in will a products. a potential up year truly indication XXXX. milestone focused for year was developmentally, as meaningful Rhythm, have setting exciting year and XXXX be an to execution, strategic XXXX commercially, So
We finished Slide cornerstone the having first the the aspects Valley. on remains of trial. Phase Rhythm. box, III the HL the highlight X which overenrolled important our we've boxes, And Rhythm X, got So of on year
the initial with prevalence the same the is half patients Xx in with as the that and suggesting little and U.S. that in of the interactions able and the in announce size epidemiology XXX Now .What's and will in the strong trial number patients concluded on opportunity their evolve with higher us form severe to the would participate in interesting particularly patient III Japan benefit further population, engagement. that regulatory all readout. U.S. U.S., highly of trial. help in today, include interactions in excited we patients have our which remains facilitate than will EMA high population dosed to with constructive top of track Japanese for about the by ensure the to and PMDA, us of Japan for U.S. independent level an a XXXX allow the the unmet call HO X,XXX primary basis filings, the of is also of authority, they motivated regulatory Japanese with are about in understand Japan a who patients, experts process were them in to Phase joined medications X,XXX our requiring there leading keeping potential continuing albeit Japan trial Japan Execution one III more firmly a XX analysis We're is medical to this Japanese work XXX which cohort half first the need than extremely a line the site to the study in development is patients. of setmelanotide were to the Phase be without the We innovative the
second it of most will, this behind forward if the plays Rhythm the become U.S. overall we think opportunity. the valuable HO opportunity Japan part could as So the portfolio opportunity
expand that forward. on and So Yann plans going epidemiology our more will
programs, With to the program, regard again acquired data progressing progress slides molecule strength show well. think a the further you before, newly will X reminding on made seen I'll Second, comment great slides. several are and we daily weekly those our both advancing Chem in so of important. of pediatric I that our XXX small couple formulation why we and of is LG from you've it
ages the of previously the EU, the first -- have of X expand to in patients we'll between year. reported, as this of filed, use and half file the U.S. U.S. sorry, X We in insert in the and the in
with over more and Third, we commercially quarter solid another in revenue, prescriptions for XX approvals reimbursement. than $XX.X million had XXX new
We a are quarter were impacted Italy. And by approvals [ with to of Spain prescriptions. policy volume in commercially cover ] a for previously reimbursement required. favorable in a state in of and than excited one requiring countries, U.S. Medicaid and a Revenues including in about documentation is approvals, has X state now and but change the the disproportionately BBS in made place continues XX those by available to Canada. single our in CIRI recent level The higher patients in policy now high response a is program
early prevalence program The of as in reimbursed other demographic in BBS, the state it work patients they a has we require in change coming this There early diagnosis, bridge provided to impact XX the off patients specific with issues. a off attestation while coverage this ophthalmology the this was policy, through came confirm situation who now is were of in unique with treatment our previously, simply and drug to program console whereas if With which free of XX physician. coverage a example, the diagnosis eye is For patients will findings quarter through any on BBS higher and treatment patient the was to quarter to million. is came program going $X read on the program, prescribing early. the no consistent an of to about a to Bridge transitioned Medicaid
patient and quarter the in this start will, the more the in U.S. grow course, good story a section. the dip in numbers very of finished Jennifer at remainder U.S. quarter, the we of of as place, provide color despite and continues to Importantly, her expected,
Slide So moving X. to
Japan, of in regulatory subjects authorities PK more and So investigational therapy conducted testing advance Typically, in in patients. Japanese be to Japanese require studies in
However, our following the into Pan or Medical Device extremely Agency, Phase we on Pharmaceutical the agreed Japanese III enroll constructive XX plan discussions have with to patients PMDA, trial. current a
those and in data PK independent no to collect be in will perform study patients, there will requirement XX Japanese subjects. an We
the study impact lines on and cohort the States to our line to top the and of Europe. pivotal Importantly, our have patients United as cohort, for be data complete them will complete additional no time filings the and said, timing to Japanese I submit added the get and in to
patients outside of Japan Specifically, of patients, orphan approval, Japan trial. which and and will the and support U.S. XX-plus we in second the in be drug designation part patients approximately of we the The to patient file XX used in Japanese be are a patients EU the will results will on finished parallel. the will Japanese first close, core seek group over-enrolled remaining from part the the who who XXX
placebo. with know or III placebo Phase you X, to setmelanotide III enrolled just Phase Slide obesity, for aged all up with endpoint regimen randomized X therapy well. trials mean The X remind on design It's hypocalomic X:X our is this therapeutic in you HO, patients titration. for on for approximately a for a XX baseline and after the trial BMI trial is which to percent So compared includes this to of setmelanotide older weeks, weeks total which the dose of change weeks from years primary XX
for as On early we LG generated data across to developed powered data a yes, early moment and to patients that, of setmelanotide an We that suggests company. in and showing has will regarded long-term date value will the with expertise quite Chem, aim hyperpigmentation consistent arm Chem's new consistent safety particularly cardiovascular given response and on acquisition based effects. LG translational and our told and oral to all working global an profile XX%, be company drug have an a could clinical who molecule. indications, in LB-XXXXX, the chemistry outcomes. side other which with experience the X, this are drug rights specific speak between and be we Slide on in not important before, adhere We confident for identified option highly announced or candidate MCXR they deep that diseases have a about we XX-month January. associated result you therapeutic are for an driver about we for excited provide important prescribed I´ll XX.X% the therapy We're patients early a of candidate XX-point could the believe treatment our and placebo their and therapy achieve the differential
more treatment. path the about treating which LBXXXXX, on A need their described, the on track volunteers the I impressed to site expected the highly developing focus HL allow anticipate diseases the formulation, decrease hypothalamic We On are the focus as robust collaborative for healthy the team X both parallel Phase with showed trial that. which for primary patients for X to MCX and the who, signal move we genetic previously transfer LG at of BMI study in move the as responsibility on be trials and of molecule X, know with have the we we by had for In will to in preclinical will remain jointly a signing rhythm. X by package to being we Slide pediatric us meantime, obesity, younger initiation months progressing in were a weeks. the of in the little be program obesity, within data transfer as largely to and causes with complete a of We dose-dependent interaction working are full
open-label by patients of The molecule similar control signal, exception SIGNAL change with endpoint, weeks. did safety, an of X trial XX in in ran consistent they the up pharmacokinetics, cardiovascular X mean Phase a be to period trial very to arms, XX-patient HO. baseline extension shows which the with or groups obesity. evaluate XX placebo-controlled followed placebo efficacy sorry, preclinical The from hypophylamic efficacy we any see loss in trial is is and not of percent setmelanotide trial open-label XX to an design Importantly, Slide originally with is trial weight the trial, with different placebo is -- in designed evaluate the BMI to the tolerability, a II This work. of hyperpation their to would weeks. dose
as are We which have to effects a quite sensitive model of agonist. to an appears to the HO, MCXR such fortunate be
On dose advances. year. small dose the safety we is aiming XXX and this look first We're [ this we advancing the half efficacy, CRO the insight relatively the Slide Metro in patients develop first a our committing have of program, in will to selected year. the as can we the is So I XX, to will expectation as ], The importantly, high us IND which into filed, dosed And tell program here. looking our trial you our are patients good that give those are range, to is to well. that have half first March of this and first weekly
which reminder, we followed we required are has toxicity Those in in parallel it Part One now. enter a effective. not a are recognized patients their reasons R&D HL be by revisit to the complete our genetic single with been once blamed will patients know disease. will patients want XX, in in anecdotes, which and into ongoing be given to for a in cohorts at for C, multiple since are data they these our chronic days. POMC pediatric with XX the That a for X running severity, of my to extension patients birth. these young the on showed cases, ascending will we in and extremely worst with X begin Day volunteer dosing the means last obesity, normal As that Despite from and Slide chronic the to study the followed And the child's not studies, toxicity long-term multiple eligible I dose disease, inability intake. food are were despite conventionally ages having is find patients an remarkable present a December. control On longer and quite cases, patients support most studies of parents deficiency enroll in we slides, which severely should the X either their age, cause underlying I as being results between couple surprise VBS, of or those
on mean at of story Slide is away graph the decrease for than axis shows BMI-Z which where plot waterfall is X this year. individual Y XX% this of takeaways. see is individual lies in can of standard Two I score, XX, the the number the slide, treatment. the patients weight child the shows with a As responded a score the you treatment think basically The to results from XX results, change BMIC show extremely more well patients. in in which the normal. The real deviation, with The
X.X showed not The For as with people patient your clinically -- highly and market specific genetic have chance high not their when obesity, X groups, remember a medication. the can course, early one to to the point additional who a modify of the medication these in is BMIZ up patients BBS will side meaningful XX. it of given importance indicated. to the the with decrease who early BMI-Z it is in the left has Expanding score in reinforces up significant the with outcomes. on was left-hand BMIZ is a as onset about the remind graph, should a you first X- therapy, The X score who be a but a X-point will above still starting the as from of intervene change X lost POMC meaningful. the meaningful changes to given clinically will only X- thinking a than to did long-term it children right, patients scores starting affected, important incrementally, quite add experiencing the better not and to confronted young label as noncompliant be cumulative their third, children in It from morbidity X to the second decrease. severely are follow X-point as safety to greater a of considered And the reinforce will that patient were early opportunity, regains it if and that earlier and causes children open trial
So label we call U.S. in forward filing European the With filed in said, expansion, I'll XXXX. QX we as to our look over the of to I and that, for Jennifer. turn
